Cancer Family
Head and Neck Neoplasm
CI-CAN-00000021Explore in graph →
Non-malignant1,572 active trials17 approved drugs142 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000021Explore in graph →
Clinical trials
6,373 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04110249 | Photoacoustic Imaging for Measuring Tumors and Normal Tissue in Patients With Head and Neck Cancer | terminated | N/A | 14 | Roswell Park Cancer InstituteOTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT01827709 | Pathological Validation of Functional Imaging in Head and Neck Squamous Cell Carcinoma | terminated | N/A | 11 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT03254927 | A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma | terminated | Phase 2 | 30 | Celldex TherapeuticsINDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
| NCT04034225 | Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN | terminated | Phase 1 / Phase 2 | 25 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Mar 24, 2023 | clinicaltrials |
| NCT02582008 | Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy | terminated | Early Phase 1 | 9 | Wake Forest University Health SciencesOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT02291055 | A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer | terminated | Phase 1 / Phase 2 | 75 | Advaxis, Inc.INDUSTRY | 1 | Mar 20, 2023 | clinicaltrials |
| NCT05338125 | Electrophysiology of the Human Pituitary Gland | terminated | N/A | 1 | Leiden University Medical CenterOTHER | 1 | Mar 13, 2023 | clinicaltrials |
| NCT02917629 | ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Mar 8, 2023 | clinicaltrials |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies(REVEAL) | terminated | Phase 1 / Phase 2 | 64 | Nektar TherapeuticsINDUSTRY | 1 | Mar 8, 2023 | clinicaltrials |
| NCT02834247 | A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors | terminated | Phase 1 | 41 | Calithera Biosciences, IncINDUSTRY | 4 | Feb 8, 2023 | clinicaltrials |
| NCT03193931 | Study Comparing Pembrolizumab With Methotrexate in Elderly, Frail or Cisplatin-ineligible Patients With Head and Neck Cancers(ELDORANDO) | terminated | Phase 2 | 47 | AIO-Studien-gGmbHOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT02449681 | Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin | terminated | Phase 2 | 30 | Rain Oncology IncINDUSTRY | 2 | Jan 12, 2023 | clinicaltrials |
| NCT04969861 | BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) | terminated | Phase 2 / Phase 3 | 1 | Nektar TherapeuticsINDUSTRY | 4 | Jan 12, 2023 | clinicaltrials |
| NCT00528294 | Phase I Trial From GRID 18F-FDG-PET Biological Imaging-guided Intensitymodulated Radiotherapy (BG-IMRT) With Patients With Recurrent or New Head or Neck Tumor in Previously Radiated Area | terminated | Phase 1 | 12 | University Hospital, GhentOTHER | 1 | Dec 20, 2022 | clinicaltrials |
| NCT04453046 | Hemopurifier Plus Pembrolizumab in Head and Neck Cancer | terminated | N/A | 2 | Aethlon Medical Inc.INDUSTRY | 1 | Dec 20, 2022 | clinicaltrials |
| NCT03258008 | Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 16, 2022 | clinicaltrials |
| NCT05219578 | RTX-224 Monotherapy in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Rubius TherapeuticsINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT04672980 | RTX-321 Monotherapy in Patients With HPV 16+ Tumors | terminated | Phase 1 | 9 | Rubius TherapeuticsINDUSTRY | 1 | Dec 8, 2022 | clinicaltrials |
| NCT03513042 | Early Response Evaluation of Proton Therapy by PET-imaging in Squamous Cell Carcinoma Located in the Head and Neck(ERM-PT-HNSCC) | terminated | — | 12 | Leiden University Medical CenterOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT04762225 | RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma | terminated | Phase 1 | 7 | Repertoire Immune MedicinesINDUSTRY | 1 | Dec 6, 2022 | clinicaltrials |
| NCT05061940 | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols. | terminated | — | 22 | Repertoire Immune MedicinesINDUSTRY | 1 | Dec 6, 2022 | clinicaltrials |
| NCT04155008 | Nutrition and Pharmacological Algorithm for Oncology Patients Study | terminated | Phase 4 | 1 | Montefiore Medical CenterOTHER | 1 | Nov 16, 2022 | clinicaltrials |
| NCT03506048 | Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer | terminated | Phase 2 | 4 | Emory UniversityOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT02437916 | Safety Study of AMG 228 to Treat Solid Tumors | terminated | Phase 1 | 30 | AmgenINDUSTRY | 5 | Nov 8, 2022 | clinicaltrials |
| NCT04242173 | Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC | terminated | Phase 2 | 3 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT02055963 | Minocycline for Postsurgical Symptom Reduction in Head and Neck Cancer | terminated | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT01891695 | OPSCC N0 Nodal Control With Reduced IMRT | terminated | N/A | 1 | Paul W. Read, MDOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT02408887 | Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Sep 27, 2022 | clinicaltrials |
| NCT04128267 | Central Pain Syndrome in Survivors of Head and Neck Cancer | terminated | N/A | 32 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Sep 19, 2022 | clinicaltrials |
| NCT02363647 | Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer | terminated | N/A | 10 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 | 61 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT03862066 | Memory Phenotype and PD-1 Inhibition Response in Oral Cancer | terminated | — | 2 | Medical University of South CarolinaOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT03930771 | Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas(TMZ-Cap) | terminated | Phase 2 | 1 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT00394147 | Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer | terminated | Phase 2 | 17 | Fox Chase Cancer CenterOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT03065218 | 99mTc Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid Cancer (DTC) Patients | terminated | Phase 4 | 4 | Medstar Health Research InstituteOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT03720158 | Enteral Omega 3 During Radiotherapy to Improve the Quality of Life and Functionality of Head and Neck Cancer Patients | terminated | N/A | 9 | Coordinación de Investigación en Salud, MexicoOTHER_GOV | 1 | Jul 25, 2022 | clinicaltrials |
| NCT02325349 | PET/CT Imaging of Angiogenesis in Lung or Head and Neck Cancers Prior or During Chemotherapy With Antiangiogenic Agents(MLAPOCHI) | terminated | Phase 2 | 1 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | terminated | Phase 1 | 49 | Genocea Biosciences, Inc.INDUSTRY | 1 | Jul 15, 2022 | clinicaltrials |
| NCT03713021 | TraceIT Tissue Marker to Mark the Primary Resection Bed Margins of Oropharyngeal Cancers | terminated | N/A | 27 | Washington University School of MedicineOTHER | 1 | Jul 12, 2022 | clinicaltrials |
| NCT03090412 | Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer | terminated | Phase 2 | 2 | Roswell Park Cancer InstituteOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT04880603 | Utility of Restrata With Split-thickness Skin Graft to Reconstruct the Forearm Donor Site | terminated | Phase 2 | 5 | Nebraska Methodist Health SystemOTHER | 1 | May 13, 2022 | clinicaltrials |
| NCT04272333 | Intratumoral Microdosing of Motolimod in HNSCC | terminated | Early Phase 1 | 1 | Presage BiosciencesINDUSTRY | 1 | Apr 14, 2022 | clinicaltrials |
| NCT04428047 | Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma(ICING) | terminated | Phase 2 | 7 | UNICANCEROTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT02419664 | Ga-68-DOTATOC -PET in the Management of Pituitary Tumours | terminated | Phase 3 | 22 | Göteborg UniversityOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT00198315 | Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma | terminated | Phase 3 | 130 | Inovio PharmaceuticalsINDUSTRY | 1 | Mar 4, 2022 | clinicaltrials |
| NCT04015336 | E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2022 | clinicaltrials |
| NCT01606566 | A Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin for Recurrent Head and Neck Cancer. | terminated | Phase 2 | 26 | PCI Biotech ASINDUSTRY | 6 | Feb 18, 2022 | clinicaltrials |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT00003777 | Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer | terminated | Phase 2 | 35 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT02874651 | ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy(ADVANCE) | terminated | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Jan 11, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Apr 10, 2023source: clinicaltrials